Author

E. Clancy-Thompson

AstraZeneca (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. Lee· 2 shared P. Wiklund· 2 shared R. M. de Real· 2 shared S. Hammond· 2 shared S. Kim-Schulze· 2 shared A. A. Melcher· 1 shared A. Burley· 1 shared A. Charap· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Lee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The HLA-E/NKG2A axis identifies a therapeutic vulnerability in BCG-unresponsive bladder cancer

Bérengère Salomé, Haocheng Yu, Daniel L Ranti, Ying‐Chih Wang, C. Bieber, Pierre‐Etienne Gabriel, Igor Duquesne, Trine Strandgaard, B. Hug, Sean Houghton, Hiranmayi Ravichandran, Elliot Merritt, S. Bang, A. Demetriou, Z. Li, , Amir Horowitz

This study identifies the HLA-E/NKG2A axis as a therapeutic target in BCG-unresponsive bladder cancer by showing its role in immune evasion and impaired effector cell function.

bioRxiv · Sep 2, 2024 · PreprintCancer Biology

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

E. C. Patin, P. Nenclares, C. Chan Wah Hak, M. T. Dillon, A. Patrikeev, M. McLaughlin, L. Grove, S. Foo, H. Soliman, J. P. Barata, J. Marsden, H. Baldock, V. Roulstone, J. Kyula, A. Burley, , K. J. Harrington

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

bioRxiv · Nov 8, 2023 · PreprintImmunology

NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer

B. Salome, J. P. Sfakianos, J. Daza, A. Charap, C. Hammer, R. Banchereau, A. M. Farkas, D. Geanon, G. Kelly, R. M. de Real, B. Lee, K. G. Beaumont, S. Shroff, Y. S. A. Wang, Y.-C. Wang, , Mariath

This study identifies NKG2A and HLA-E as an alternative immune checkpoint axis in bladder cancer, showing NKG2A+ CD8 T cells can bypass HLA-ABC loss through TCR-independent cytotoxicity.

bioRxiv · Mar 4, 2022 · PreprintImmunology